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SUMMARY
Background
Short-chain fatty acids (SCFA) produced through fermentation of nondi-
gestible carbohydrates by the gut microbiota are associated with positive
metabolic effects. However, well-controlled trials are limited in humans.
Aims
To develop a methodology to deliver SCFA directly to the colon, and to
optimise colonic propionate delivery in humans, to determine its role in
appetite regulation and food intake.
Methods
Inulin SCFA esters were developed and tested as site-speciﬁc delivery vehicles for
SCFA to the proximal colon. Inulin propionate esters containing 0–61 wt% (IPE-
0–IPE-61) propionate were assessed in vitro using batch faecal fermentations. In
a randomised, controlled, crossover study, with inulin as control, ad libitum food
intake (kcal) was compared after 7 days on IPE-27 or IPE-54 (10 g/day all treat-
ments). Propionate release was determined using 13C-labelled IPE variants.
Results
In vitro, IPE-27–IPE-54 wt% propionate resulted in a sevenfold increase in propi-
onate production compared with inulin (P < 0.05). In vivo, IPE-27 led to greater
13C recovery in breath CO2 than IPE-54 (64.9 vs. 24.9%, P = 0.001). IPE-27 also
led to a reduction in energy intake during the ad libitum test meal compared with
both inulin (439.5 vs. 703.9 kcal, P = 0.025) and IPE-54 (439.5 vs. 659.3 kcal,
P = 0.025), whereas IPE-54 was not signiﬁcantly different from inulin control.
Conclusions
IPE-27 signiﬁcantly reduced food intake suggesting colonic propionate plays
a role in appetite regulation. Inulin short-chain fatty acid esters provide a
novel tool for probing the diet–gut microbiome–host metabolism axis in
humans.
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INTRODUCTION
One major function of the gut microbiota is the metabo-
lism of nondigestible carbohydrates (NDC), which leads
to the production of short-chain fatty acids (SCFA) as
the major end-products. SCFA have been shown to have
a range of beneﬁcial effects, including improved immune
function, adiposity and glucose regulation albeit the data
come almost exclusively from animal models.1–5 Compa-
rable mechanistic data in humans are largely lacking
because of the difﬁculty in selectively and controllably
manipulating SCFA production in human intervention
studies. The discovery of free fatty acid receptors (FFAR
2/3), for which SCFA appear to be the natural ligands,
has provided a putative mechanism of action for SCFA
and may in part explain some of the beneﬁcial effects
observed from dietary NDC consumption.6–8 High intake
of fermentable NDC has been shown to inﬂuence body
composition in animals,9 promote weight loss in
humans10 and improve glucose homoeostasis in both
animals11 and man.12 NDC ingestion stimulates the
release of glucagon-like peptide (GLP-1) and peptide YY
(PYY), resulting in a reduction in food intake in ani-
mals13 and humans,14 albeit at doses that exceed typical
daily NDC intake. SCFA have also been shown to
increase GLP-1 and PYY secretion in animals15, 16 and
in man,17 suggesting that SCFA may, at least in part,
mediate the effects of NDC on appetite regulation. How-
ever, UK NDC intake (major component of dietary
ﬁbre), has like many Western societies remained well
below the recommended levels, at around 15 g/day
(measured as nonstarch polysaccharide in the UK) and
16 g/day dietary ﬁbre in the USA.18, 19 Alternative ways
of optimising colonic SCFA production may be needed.
Of the SCFA produced in the colon, propionate has
highest afﬁnity for FFAR 2, and a lower binding afﬁnity
for FFAR 3.7 Oral propionate supplementation has been
investigated in experimental studies of appetite regula-
tion in humans,20, 21 but its poor organoleptic properties,
short-circulating half-life and the fact that it is absorbed
in the proximal small intestine limit its use as a food
supplement targeting large intestinal FFAR 2. To induce
large changes in propionate production, while avoiding
the unwanted gastrointestinal side effects of high NDC
diets, requires a more targeted approach. Recently, we
described the ﬁrst-in-man studies showing that propi-
onate, when delivered to the colon, can induce appetite
regulation, improve metabolic control and play a role in
weight management.22 This study was, to the best of our
knowledge, the ﬁrst to translate direct observations from
propionate supplementation in animal studies into a ran-
domised, controlled trial in humans, whereby propionate
was targeted to the main site of its production, the prox-
imal colon.
Targeting small molecule delivery to the large intestine
is challenging because the vector has to avoid absorption
in the small intestine, resist digestion by brush-border
and exocrine enzymes and thereafter selectively release
its small molecule payload in the large intestine. Tech-
niques for small molecule colonic delivery such as encap-
sulation, using fermentable polymer coatings,23 pH and/
or time-dependant release24 and direct instillation, using
SCFA enema25 are limited to relatively low dosing regi-
mens or are unsuitable for population-level interventions.
The binding afﬁnity between FFAR and SCFA appears
adapted for the relatively high SCFA concentrations
found in colonic environment, resulting to a key speciﬁ-
cation of any colonic delivery system for SCFA: it must
be capable of inducing signiﬁcant change in the large
colonic SCFA pool. Using observations from sudden
death victims, SCFA contents of the caecum were 69.1,
25.3 and 26.1 mmol/kg contents for acetate, propionate
and butyrate respectively.26 This suggests the caecum
alone has a propionate pool size of 1.87 g/kg contents.
Combining stoichiometric equations for NDC fermenta-
tion27 and National Diet Nutrition Survey data18 of
habitual ﬁbre intake suggests that the average adult 15 g/day
nonstarch polysaccharide intake in the UK yields a mini-
mum of 0.4 g of propionate production per day. We
therefore set a threshold of delivering >2 g/day propi-
onate to induce a ﬁvefold increase in daily propionate
production and broadly equivalent to fermentation of
90 g of NSP per day. SCFA functionalised starches have
been used in enteric coating for colon-speciﬁc drug
delivery28 and the concept was extended to starch SCFA
esters as a prodrug delivery system for SCFA to the
colon.29 However, the choice of starch as a starting
material leads to complexities in synthesis, characterisa-
tion and determination of SCFA delivery efﬁcacy because
of the variable effects of the chemical modiﬁcations on
the nature and digestibility of the starch itself. Starch sol-
ubilisation and functionalisation also requires highly
polar organic solvents leading to high purity require-
ments in downstream processing for a food-grade mate-
rial. In the present study, we describe the production
and optimisation of inulin propionate esters with favour-
able organoleptic properties and designed to release pro-
pionate within the large intestine to facilitate the study
of appetite regulation. Our choice of inulin was
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predicated on the fact that inulin is water soluble and
amenable to aqueous-based functionalisation and that its
gastrointestinal handling had been well charac-
terised.30, 31 Our aim was therefore to develop suitable
inulin propionate esters (IPE) for highly efﬁcient colonic
propionate delivery and to assess the effects of IPE vari-
ants on appetite and food intake.
MATERIALS AND METHODS
Inulin was used as the carrier (Beneo HP; DSKH, Lon-
don, UK). Inorganic reagents (Sigma-Aldrich, Dorset,
UK) and propionic anhydride (Acros Chemicals/Fisher,
Loughborough, UK) were of the highest purity available.
Activated charcoal [4 mm pellets from coconut shell
(Eurocarb, Bristol, UK)] was used as the primary clean-
up column. Dialysis was carried out overnight using a
1000 MWCO tubular membrane, which could be sealed
at both ends (Spectra-Por, Breda, The Netherlands). All
water used in synthesis, column conditioning and wash-
ing was deionised with >15 MΩ resistivity.13C-labelled
(1-13C)2 propionic anhydride was purchased from Cam-
bridge Isotopes Limited (CK Gas, Hampshire, UK) as a
custom synthesised product.
Synthesis and characterisation of IPE
The following describes the route to IPE with a target
degree of esteriﬁcation of 0.8, on average every 1 in 1.25
fructose moieties will have one hydroxyl group esteriﬁed.
This equates to a propionate loading of 27 wt%. The
degree of esteriﬁcation (propionate loading) can be var-
ied by the amount of propionic anhydride added and the
following is provided by way of exemplar of a route to
food-grade IPE. Inulin HP (450 g; Beneo-Orafti Food
Ingredients, Tienen, Belgium) was dissolved in 2 L deio-
nised water and transferred to a 3 L water-cooled jack-
eted reactor with overhead stirring and continuous pH
monitoring and allowed to cool to ~ 25 °C. Propionic
anhydride (360 mL, 2.8 moles) and NaOH (400 mL,
25% w/v) were set up in dropper funnels above the reac-
tor. The pH was adjusted to 8.25 by dropwise addition
of NaOH and the addition of propionic anhydride com-
menced when the temperature in the reaction mixture
was <20 °C. The rate of addition of reagents was such
that the pH remained between 8 and 8.5 and the tem-
perature remained <20 °C. Once addition of propionic
anhydride was complete the reaction mixture was
allowed to pH stabilise and thereafter adjusted to pH 2
with concentrated HCl. Immediately, the reaction mix-
ture was allowed to ﬂow through an activated carbon
(4 mm granular coconut shell; Eurocarb) column which
had been thoroughly washed and conditioned with
0.2 M HCl. The column contained ~ 1 kg activated char-
coal and the reaction mixture was allowed to ﬂow
through at approximately 0.5 L/h. Activated carbon has
a higher afﬁnity and sequestration capacity for propionic
acid compared with the anionic form–propionate.32 The
reaction mixture recovered from the column was
adjusted to pH 2 with concentrated HCl and passed
through a second column prepared in an identical fash-
ion to the ﬁrst column. The reaction mixture was sub-
jected to overnight dialysis in dialysis tubing (Spectra/
Por 6, 1000 MWCO; Spectrum Europe B.V., Breda, the
Netherlands). The reaction mixture was collected and
again adjusted to pH 2 before spray drying (Buchi, Old-
ham, UK) in an inert N2 gas ﬂow. The ﬂow of liquid, N2
and nebuliser temperature were such that an outlet tem-
perature of ~100 °C was maintained.
IPE was characterised by infrared spectroscopy for the
presence of an ester bond, GC-FID to establish levels of
free propionate, salt content and heavy metal content,
and subjected to microbiological testing of the ﬁnal pro-
duct (details available in supporting material).
Microbiota metabolism of IPE in vitro
The fermentation proﬁles of inulin (control) and IPE
variants ranging from 10% to 61% loading (equating to a
degree of esteriﬁcation range of 0.25–2.5) were tested
using batch faecal cultures.33 Inulin was selected as con-
trol to account for SCFA production from the NDC
backbone. Faecal samples were collected from three
healthy volunteers (who had no history of gastrointesti-
nal complaints and were antibiotic free for 6 months
prior to faecal collection) and prepared separately in
triplicate for each substrate. The composition of the fae-
cal batch fermentation systems is described in detail in
supporting information. The absolute production of
SCFA (at 24 h), molar ratios and yield of propionate
from IPE (calculated after subtracting propionate pro-
duction from inulin) were calculated. The efﬁciency
(% of theoretical propionate yield) was also calculated.
The ability of a number of esterase enzymes to release
propionate was tested using the standard esterase kit avail-
able from Sigma-Aldrich (Poole, UK). Brieﬂy, IPE, ethyl
propionate (positive control) and water (negative control)
were incubated in phosphate buffer along with esterases
from Candida lipolytica, Mucor miehei, Pseudomonas ﬂuo-
rescens (recombinant from E. coli), Streptomyces dias-
tochromogenes (recombinant from E. coli), horse liver and
hog liver. Propionate release was determined by GC.
Detailed methods are available in supporting material.
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IPE palatability
A short consumer palatability study was undertaken to
assess the organoleptic properties of IPE incorporated
into food products. This feasibility study aimed to deter-
mine if IPE could be practically incorporated into food
products masking the poor organoleptic properties of
free propionate. Full details on the methodology are
available in supporting information.
RANDOMISED, CROSSOVER STUDY TO DETERMINE
EFFECTS OF IPE VARIANTS ON FOOD INTAKE
Subjects
Overweight healthy males were the target cohort for this
study to mitigate against the effects of the menstrual
cycle on appetite regulation and food intake. Nine
healthy males were recruited to characterise which IPE
preparation optimises delivery to and release of propi-
onate in the colon. The characteristics of the cohort were
(mean  S.E.M.) age (38  9 years), weight (98.36 
3.0 kg) and body mass index (BMI; 29.8  1.5 kg/m2)
respectively.
Participants were recruited via local advertising. The
inclusion criteria for all three investigations were age 21–
65 years and BMI range 25–35 kg/m2. Exclusion criteria
were smoking, substance abuse, use of medications, a
change in body weight >5 kg in the previous 3 months,
medical or psychiatric illness, assessed by a self-reported
medical questionnaire. The study was approved by Col-
lege of Medical, Veterinary and Life Sciences ethics com-
mittee for nonclinical research in human volunteers at
the University of Glasgow. All studies were carried out
in accordance with the Declaration of Helsinki. The
study was registered with ClinicalTrials.gov
(NCT02229500).
Study design
This study was a four-wing randomised crossover design
where each volunteer acted as their own control. The
study aimed to characterise an IPE preparation that
maximises the bioavailability of propionate to the colon.
After a familiarisation/screening visit which also served
as a baseline study day, volunteers were randomly allo-
cated to one of three treatments using a random number
generator. The principal grant holder who did not carry
out the experimental trials performed the random alloca-
tion. The allocation of codes for each supplement and
their respective participant ID was sent to the investiga-
tor carrying out the experimental trials, who then
enrolled participants with the allocated supplement. Both
the investigator running the experimental trials and the
participants were blinded to the contents of the supple-
ment. The location for the experimental visit was the
Clinical Research Facility (CRF) at Glasgow Royal Inﬁr-
mary. Participants visited the CRF on four occasions
throughout the study. The screening trial acted as a
familiarisation trial and after consuming a supplement
(detailed later) for 1 week, participants re-visited the
CRF on day 7 of supplementation. At least 2-week wash-
out period was allowed between supplements. Supple-
mentation periods took place under free-living
conditions and washout involved normal habitual diet
and lifestyle. Participants were asked to record their food
intake for 3 days prior to the CRF visit and replicate this
prior to each study visit. As a measure of compliance for
supplement intake, subjects were requested to return
empty sachets to the investigator. The primary outcome
measure for this study was area under the curve of
breath 13CO2 enrichment (a proxy for the extent of pro-
pionate release). Participants were also asked to provide
a stool sample during or immediately after each visit to
the CRF to assess stool 13C output. Urine was collected
for 24 h post-dose to assay urinary 13C output.
At the end of the screening/familiarisation trial, par-
ticipants were provided with the coded sachets contain-
ing the supplement and were asked to consume this with
breakfast for 6 days. The supplement was either IPE-27,
IPE-54 or inulin, each containing 10 g/day single dose.
On day 7, participants attended the CRF for their next
visit, which lasted 8 hours. At the end of the 2nd visit,
participants were provided with the next supplement in
identical sachets and were advised to undergo a mini-
mum 14-day wash out period, prior to consumption of
the supplement (consumption started on day 15). Thus
after another 7 days (on day 21), volunteers reported to
the CRF for a repeat measurement day. Following a fur-
ther 14-day washout, participants consumed the ﬁnal
supplement and returned to the CRF 7 days after supple-
mentation for repeat measurement day. Washout often
lasted longer than 14 days to accommodate volunteer
lifestyle. On the CRF study days consuming IPE variants,
a sachet containing the respective unlabelled IPE mixed
with a 13C-labelled IPE (300 mg of 13C IPE-27 or
100 mg of 13C IPE-54 providing similar amounts of tra-
cer) of identical composition was provided with a stan-
dard breakfast. Blood was collected via indwelling
venous cannula (inserted into an antecubital vein) and
baseline blood samples were collected into heparin-
coated tubes containing 0.2 mL of aprotinin (Sigma-
Aldrich) at 10 min and 0 min and then at 60 min
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intervals up to 7 h assess plasma PYY and GLP-1
concentrations (further details available in supporting
material).
Ad libitum food intake and appetite
On each study day, participants were offered standard
breakfast, a balanced meal for lunch at 4 h after break-
fast and at the end of the study day (at 8 h following
breakfast), food intake was assessed by offering a free
buffet meal. Breakfast included a plain scone, jam, butter
and orange juice (calories, 266 kcal; protein, 2.8 g; fat
6.5 g, CHO, 48.9 g), while lunch included a cheese sand-
wich, an orange, orange juice and strawberry yoghurt
(calories, 676.9 kcal; protein, 28.6 g; fat, 23 g; CHO,
92,7 g). The ad libitum meal included a selection of
sandwiches prepared by the catering service of the hospi-
tal, toffee yoghurt, an orange and an orange juice (calo-
ries, 1440 kcal; protein, 52 g; fat, 46.5 g, CHO, 209 g).
The meals were weighed before and after consumption
with the use of a digital kitchen scale. The nutritional
information for all foods was offered by the catering ser-
vice and thus accurate energy and macronutrient intake,
based on the ﬁnal weight consumed, was calculated for
all meals. Furthermore, participants were asked to repli-
cate their evening meal on the evening preceding the
trial day. At baseline and every 30 min, participants were
asked again to rate their feelings of hunger and fullness
using visual analogue scales (VAS; further details avail-
able in supporting material).
13C analyses
CO2 was collected serially over 12 h followed by one fur-
ther sample collection at 24 h (to verify return to natural
abundance levels) by exhaling alveolar breath through a
straw into Exetainers (Labco, Ceredigion, UK). 13CO2
enrichment was determined by isotope ratio mass spec-
trometry (IRMS). 13CO2 above baseline (post-dose –
pre-dose 13CO2; ppm xs
13C) and cumulative 13CO2
excretion were also calculated. CO2 production rate was
estimated from body surface area and a physical activity
level factor of 1.3 was used to allow calculation of cumu-
lative 13C dose recovered (%).34 Stool and urine 13C out-
put were also determined using IRMS (detailed methods
in supporting material).
Data Analysis
Results are expressed as mean  s.d. or S.E.M. (where
indicated). Results were compared by ANOVA with post
hoc analysis. Statistical analysis was conducted on SPSS 18
(Chicago, IL, USA).
RESULTS
Synthesis and characterisation of IPE
The yield of IPE from inulin was ~70%. The major losses
of product occurred on the column, when precipitation
started to occur, and in the spray dryer, where product
collected on the vaporisation chamber and ﬁlter. Post-
reaction pH control was necessary to maintain propi-
onate in the acidic form to facilitate its removal on the
column. In addition, the spray drying conditions pro-
moted volatilisation of free propionic acid, further puri-
fying the product. The degree of esteriﬁcation of the
ﬁnal product was 0.74  0.02, with a free propionate
content (of all available propionate) of 1.25  0.30%
(see supporting material for further information on IPE
purity).
In vitro and in vivo results
Not all IPE preparations were equally well fermented.
Propionate production in faecal fermentations was signif-
icantly higher in variants containing 27–54 wt % propi-
onate (IPE-27–IPE-54; Figure 1A,B). IPE variants in the
range 27–54% propionate yielded similar levels of propi-
onate and IPE-27 appears to be the most efﬁcient at
releasing propionate (variant with maximal efﬁciency
and yield; Figure 1C) and this decrease in efﬁciency
appeared to mirror the decrease in solubility with
increasing degree of esteriﬁcation (Figure 1D). Propi-
onate release from IPE incubated with esterases was low
indicating that, at least for the species tested, de-esteriﬁ-
cation appeared limited (Figure S1 in Data S1).
The data obtained from human experiments indicated
that recovery of 13C in breath continued for more than
12 h (Figure 2a), but appeared to have returned almost
to baseline abundance by 24 hrs (data not shown). IPE-
27 led to signiﬁcantly greater 13C recovery in breath
CO2 (64.9 vs. 24.9%, P = 0.001; Figure 2b) compared
with IPE-54. Only fasting PYY was elevated when com-
paring treatments with control, with a signiﬁcantly lower
incremental area under the curve (iAUC) observed for
IPE-54 compared with inulin control for PYY only
(Results section and Figures S2a–d in Data S1). There
was no difference in stool 13C recovery (Figure S2 in
Data S1) which equated to a mean (SEM) recovery of
0.13 (0.11) and 0.39 (0.16) % of administered tracer for
IPE-54 and IPE-27 respectively using average daily stool
output of 106 g/day for UK adults.35 Similarly, there
was no difference in urine 13C enrichment, which barely
deviated from isotopic natural abundance (Figure S3 in
Data S1).
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IPE appears palatable to participants and indistin-
guishable from inulin when consumed in certain foods
(Figure S4 in Data S1). This would appear to discount
an adverse organoleptic effect from consuming IPE. IPE-
27 led to a signiﬁcant reduction in energy intake during
the ad libitum test meal compared with both inulin
(439.5 vs. 703.9 kcal, P = 0.025) and IPE-54 (439.5 vs.
659.3 kcal, P = 0.025; Figure 3a). IPE-54 was not signiﬁ-
cantly different from inulin control for the ad libitum
test meal. IPE-27 led to signiﬁcantly lower total energy
intake compared with IPE-54 (1167.6 vs. 1432.9 kcal,
*P = 0.016) but only a trend towards lower intake com-
pared with inulin control (1167.6 vs. 1444.6 kcal,
P = 0.076; Figure 3b). There were no associated differ-
ences observed in the visual analogue scales (Figures S5
and S6 in Data S1).
DISCUSSION
We have designed a process to produce kg quantities of
an inulin SCFA ester with desirable characteristics for
targeted colonic delivery of SCFA to the colon. For inu-
lin propionate ester (IPE), our study demonstrates a
nonlinear relationship between propionate release
in vitro and the degree of IPE esteriﬁcation. Our study
further demonstrated that an IPE variant with 27% (wt/wt)
propionate loading is more efﬁcient at releasing propi-
onate when compared with an IPE variant with 54%
loading and that the decrease in efﬁciency of IPE vari-
ants mirrors the decrease in solubility of IPE as more
hydroxyl groups are replaced by propionyl groups. The
fermentation proﬁle of IPE-27 conﬁrmed our earlier
ﬁndings22 and the present study demonstrates that
higher degrees of esteriﬁcation (54%) does not appear to
lead to increased propionate release in the colon, mirror-
ing our in vitro data. Finally, consumption of IPE-27
was associated with appetite suppression as measured
through ad libitum food intake, whereas IPE-54 did not
suppress food intake.
We have selected to work with IPE-27 because it is
the IPE variant with the highest degree of esteriﬁcation
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that remains water soluble all the way through the
downstream processing. In previous work, we postulated
that 10 g IPE-27 releases an amount of propionate which
approximates to a 2.5-fold increase in daily colonic pro-
pionate production (based upon stoichiometric propi-
onate production from habitual dietary ﬁbre intake).22
These are levels sometimes consumed in populations
with ‘high ﬁbre’ intake with no detrimental effects.
Moreover, in a 6-month intervention with IPE-27 (10 g/
day), participants reported limited side effects and simi-
lar to the inulin control intervention.22
A previous study based on starch esters has suggested
that a targeted approach is potentially feasible for modu-
lating colonic SCFA.29 Direct evidence of regional SCFA
availability is, however, difﬁcult to monitor without an
isotopic approach. Starch is also a complex carbohydrate,
and different starch fractions have different physiological
fates. Some fractions are digestible and some resistant,
becoming available for fermentation.36 Esteriﬁcation of
starch by chemical means is nonspeciﬁc, resulting in ran-
dom esteriﬁcation of all starch fractions. Clarke et al.
estimated that 30% of bound butyrate from their ester
preparation was released in the small intestine and ~60%
released in the colon. SCFA have complex physiological
roles, involving receptor-mediated responses in the intes-
tine and metabolic effects in other extra-intestinal
organs, which may be receptor independent.37–39 Delin-
eating the mechanism of action in human studies there-
fore requires discrete site-directed delivery. We therefore
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Figure 2 | Proﬁle of 13CO2 recovery (a) and mean (s.d.)
cumulative 13C recovery (b) from propionate release
and oxidation following supplementation with the
IPE-27 and IPE-54. Breath 13 CO2 excretion for IPE-27
was higher (from 1 h onwards) compared with IPE-54
(P < 0.05). IPE-27 led to signiﬁcantly greater 13C
recovery in breath CO2 (64.9 vs. 24.9%, P = 0.001)
compared with IPE-54.
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Figure 3 | Mean (s.d.) total energy intake (a; kcal) and
ad libitum buffet meal energy intake (b; kcal) during
the experimental day following 7-day supplementation
with IPE-27, IPE-54 or inulin. IPE-27 led to signiﬁcantly
lower total energy intake compared with IPE-54 (1167.6
vs. 1432.9 kcal, *P = 0.016) but only a trend towards
lower intake compared with inulin control (1167.6 vs.
1444.6 kcal, P = 0.076). IPE-27 led to a signiﬁcant
reduction in energy intake during the ad libitum test
meal compared with both inulin (439.5 vs. 703.9 kcal,
P = 0.025) and IPE-54 (439.5 vs 659.3 kcal,
P = 0.025). IPE-54 was not signiﬁcantly different from
inulin control.
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set a high threshold for delivery of propionate
speciﬁcally to the colon. We have concentrated on using
an inulin carrier molecule because it has a simple linear
structure, desirable chemical characteristics (including
water solubility) and the extensive published data regard-
ing its low level of digestion in the human gastrointesti-
nal tract.40, 41 We have previously reported that
propionate derived from IPE-27 appears in the plasma
propionate pool.22
There is considerable interest in the modulation of
speciﬁc SCFA in the colon because it is now recognised
that they may have roles beyond simply acting as meta-
bolic substrates. The role of SCFA in metabolic health,
appetite regulation and energy homoeostasis has recently
been extensively reviewed.42–45 FFAR 2 and 3 are
expressed in the terminal ileum and colon, and are acti-
vated by SCFA at the concentration range found in the
colon, suggesting SCFA may mediate their effects via
these receptors. SCFA-driven anorexigenic gut hormone
production has been demonstrated both in animals15, 16
and in man.17 Previous work has shown that high-ﬁbre
diets associated with SCFA production induce improved
glucose tolerance at subsequent meals; the so-called ‘sec-
ond meal effect’.46–48 Our data also demonstrate that
increased propionate release in the colon leads to a
reduction in energy intake during an ad libitum buffet
meal. We have shown previously a similar ﬁnding which
in an acute setting appears to be mediated by the anorex-
igenic gut hormones GLP-1 and PYY.22 In the present
study, however, only fasting PYY was signiﬁcantly ele-
vated (for both IPE treatments) but not postprandial hor-
mone release compared with control (although a lower
iAUC was observed for IPE-54 compared with control).
The breath 13CO2 excretion data suggests an extended
timescale for propionate release from IPE with an appar-
ent increase at 10–12 h post-dose. This elongated release
of propionate may be one explanation for the elevated
fasting response but further work is necessary to deter-
mine the dynamics of SCFA production and gut hor-
mone response as we have previously observed a
diminishing gut hormone response over time on IPE sup-
plementation.22 An interesting ﬁnding arising from the
present study is that IPE variants with an intermediate
degree of esteriﬁcation led to a lower total energy intake
and ad libitum energy intake compared with a higher
degree esteriﬁcation variant. This coincides with the ﬁnd-
ing that more propionate became available from IPE-27,
as demonstrated by the greater 13CO2 recovery in the
breath compared to IPE-54. Our previous work demon-
strated that 82.9  2.3% of the 13C recovered in breath
over 24 h appeared coincident with or after breath H2
onset release when IPE-27 was consumed.22 The early
peak in breath 13CO2 observed with IPE-54 was likely
due to the higher free (labelled) propionate content (de-
tails in supporting material) compared with IPE-27. Free
propionate is rapidly oxidised to breath 13CO2 when
given orally (data not shown) in an analogous fashion to
13C acetate which is used in gastric emptying breath
tests.49 Interestingly, this divergence in tracer recovery in
breath was not mirrored in stool output. There are sev-
eral potential limitations to the stool collection. Firstly,
only a single post-tracer stool sample was collected. The
particularly onerous burden on participants of 3-day or
5-day stool collection was a high barrier to participation
in the study and unrealistic in this setting. Thus, a signiﬁ-
cant fraction of the tracer may have been excreted in the
later stools particularly if propionate effects gut transit
times. There is however conﬂicting evidence to support
the role of SCFA as modulators of colonic activity and
thus whether propionate release inﬂuenced gut transit is
unknown.15, 50 We have previously observed little effect
of IPE on gastric emptying.22 IPE-54 is more lipophilic
than IPE-27 and therefore uptake and sequestration into
micelles and selective lymphatic uptake is a potential
mechanism leading to reduced bioavailability IPE to colo-
nic fermentation. IPE (average MW > 5000 Da) is unli-
kely to be absorbed directly either by active or passive
absorption mechanisms across the gut wall. This speciﬁc
inulin product was chosen because of the absence of
mono- and disaccharides. Nanoparticles can be seques-
trated in the gut by selective lymphatic uptake and is
dependent on their lipophilicity.51 Urine 13C analysis sug-
gests that little tracer was excreted in the urine because
the isotopic abundance in urinary carbon barely deviated
from natural abundance.
Taken together this study demonstrates that the com-
position of inulin SCFA esters is critical to their intended
use. Increasing the propionate content of the ester, on
the face of it desirable to increase the delivery of propi-
onate to the colon, is not linearly related to propionate
delivery to the large intestine. The properties of the
molecule appear to be critical to manipulating SCFA
production in the colon and each inulin SCFA ester
should be tested using isotopic proﬁling to ensure appro-
priate release proﬁle. Water solubility appears to be an
important factor in determining the release kinetics of
SCFA from the ester. This study further observed signiﬁ-
cant reductions in energy intake at a buffet meal when
consuming IPE-27, but not IPE-54, compared with inu-
lin control, by investigating the effects of different
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propionate content in IPE intake on appetite, reﬂected
by energy intake consumed in an ad libitum meal. The
selective manipulation of propionate and comparison
with inulin as control provides strong evidence for pro-
pionate as a regulatory signal from the colon involved in
appetite regulation22 and suggests that IPE-27 is an efﬁ-
cient inulin propionate ester to induce regulation of
appetite and food intake. This study demonstrates that
selective modulation of individual SCFA can be achieved
by inulin SCFA esters and that SCFA may have impor-
tant regulatory roles in human physiology. Further work
is needed to fully elucidate the roles of other SCFAs in
human health.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Propionate production from incubation of
IPE-27 and ethyl propionate (EP; positive control) from
esterases from Candida lipolytica, Mucor miehei, Pseu-
domonas ﬂuorescens (recombinant from E. coli), Strepto-
myces diastochromogenes (recombinant from E.coli),
horse liver and hog liver. Data are expressed and % of
theoretical propionate recovery.
Figure S2. Plasma PYY concentration versus time (Fig-
ure 2A), plasma PYY AUC, AUC0–180, AUC180–420 and
iAUC (Figure 2B) and plasma GLP-1 concentration versus
time (Figure 2C), plasma GLP-1 AUC, AUC0–180,
AUC180–420 and iAUC (Figure 2D). * indicates signiﬁcant
differences (P < 0.05) versus inulin control treatment.
Figure S3. Fractional stool 13C recovery x 100 (%) per
gram wet weight. Participants followed a 6-day supple-
mentation regimen followed with replacement of the dose
on day 7 with either 100 mg of 13C-IPE-54 or 300 mg of
13C-IPE-27. In both studies, the carboxyl carbon (1-13C)
of the propionyl moiety was labelled. Data are
Mean  SEM; n = 9.
Figure S4. 24 hr urine 13C enrichment (abundance)
after ingestion of 13C labelled IPE-27 and IPE-54 from the
cross over trial. Data are expressed as mean (SEM) as d13C
(0/00).
Figure S5. Comparison of the organoleptic properties
of control, inulin and inulin propionate (IPE-27) in choco-
late milkshake (A) and heated tomato soup (B) (n = 15).
Values are mean and SEM scores for visual analog scale
assessment of how pleasant the material was to consume.
**P < 0.01 and *P < 0.05.
Figure S6. Subjective ratings of appetite following 7 day
supplementation with inulin, IPE-54 and IPE-27. Ten
grams of inulin, IPE-54 or IPE-27 was ingested with an
identical evening meal and with a standardized breakfast
the following morning. A. Hunger, B. Satiety, C. Fullness,
and D. Prospective food consumption (PFC), E. Desire to
eat. Ratings were made using 100 mm visual analogue
scales (VAS), with extreme statements anchored at each
end of the rating scale (e.g. 0 mm Not at all hungry,
100 mm Extremely hungry). Data are mean  SEM;
n = 9.
Figure S7. Visual analogue scale area under the curve
for the period 0–480 min (AUC0–480; mm 9 min) data
for each rating is also shown. Data are mean  SEM;
n = 9.
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